Eli Lilly (LLY) news

Older LLY news events, each with the realized, point-in-time move the market made — page 3 of 8. Back to the LLY overview → · Full LLY reaction history →

Latest news

Recent LLY events, each with its measured reaction. (Page 3 of 8.)

DateHeadlineEventSource5-minTo close
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetesPress releasePR Newswire+0.61%+0.38%
Lilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitisPress releasePR Newswire-0.15%-0.29%
Form PRE 14A ELI LILLY & Co For: Mar 06SEC filing · Form PRESEC EDGAR-0.16%+2.18%
Lilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patientsPress releasePR Newswire+0.13%-0.68%
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areataPress releasePR Newswire+0.88%+3.40%
Chondrosarcoma Treatment Market Forecasts Robust Growth During the Forecast Period (2026-2036) as Oncology Pipeline Strengthens | DelveInsightPress releasePR Newswire+0.88%+3.40%
Lilly's oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The LancetPress releasePR Newswire-0.27%-0.20%
Zepbound (tirzepatide), the most prescribed weight management medication in 2025, now available in multi-dose KwikPenPress releasePR Newswire-0.96%+1.09%
Patients with Crohn's disease maintained steroid-free remission for three years with Lilly's Omvoh (mirikizumab-mrkz)Press releasePR Newswire+0.14%+0.79%
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweightPress releasePR Newswire-0.45%-1.14%
Scribe Therapeutics Achieves Second Success Milestone for In Vivo Program in Collaboration with Eli Lilly and CompanyPress releaseBusiness Wire+0.37%-0.91%
Lilly to participate in TD Cowen's 46th Annual Health Care ConferencePress releasePR Newswire+0.37%-0.91%
Lilly's Retevmo (selpercatinib) delivers substantial event-free survival benefit as an adjuvant therapy in early-stage RET fusion-positive lung cancerPress releasePR Newswire+0.37%-0.91%
USOPC Announces the Team USA Athlete Recovery Program in Partnership with Eli Lilly and CompanyPress releasePR Newswire+0.37%-0.91%
Form 10-K ELI LILLY & Co For: Dec 31SEC filing · Form 10-KSEC EDGAR+0.06%-0.82%
Lilly to acquire Orna Therapeutics to advance cell therapiesPress releasePR Newswire+1.74%-3.36%
Form 8-K ELI LILLY & Co For: Feb 04SEC filing · Form 8-KSEC EDGAR+0.26%+2.80%
Lilly reports fourth-quarter 2025 financial results and provides 2026 guidancePress releasePR Newswire+0.26%+2.80%
Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facilityPress releasePR Newswire+0.25%+0.95%
Jaypirca® (pirtobrutinib), the First and Only Non-Covalent (Reversible) BTK Inhibitor, Now Available in Canada for Adult Patients with Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaPress releaseCanada Newswire+0.67%-2.31%
Lilly confirms date and conference call for fourth-quarter 2025 financial results announcementPress releasePR Newswire+0.20%+1.00%
Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancerPress releasePR Newswire+1.42%+2.09%
Ontario Pioneers Access to Treatment for Severe Alopecia Areata with Lilly's Olumiant®Press releaseCanada Newswire-0.51%-0.78%
Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public MarketsPress releaseBusiness Wire-0.14%-1.63%
Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweightPress releasePR Newswire+0.27%+0.07%
Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseasesPress releasePR Newswire+1.15%-2.56%
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trialPress releasePR Newswire+2.41%+1.45%
Lilly to participate in J.P. Morgan Healthcare ConferencePress releasePR Newswire+0.53%+0.03%
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancerPress releasePR Newswire-0.00%+1.04%
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trialPress releasePR Newswire-1.01%-0.36%
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisitionPress releasePR Newswire+0.35%-2.12%
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in AlabamaPress releasePR Newswire-0.22%-0.55%
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLLPress releasePR Newswire+0.35%-2.12%
Carolyn Bertozzi returns to Lilly board of directorsPress releasePR Newswire-0.20%-0.10%
Lilly declares first-quarter 2026 dividendPress releasePR Newswire+0.16%+0.39%
Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)Press releasePR Newswire-0.86%-1.30%
U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitorPress releasePR Newswire-0.15%-0.32%
Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer SymposiumPress releasePR Newswire+1.08%+3.37%
Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual MeetingPress releasePR Newswire+0.01%+0.39%
Form 8-K ELI LILLY & Co For: Nov 18SEC filing · Form 8-KSEC EDGAR+0.52%+0.90%
Lilly announces plans to open Lilly Gateway Labs site in PhiladelphiaPress releasePR Newswire+0.77%+1.89%
Lilly to participate in Citi's 2025 Global Healthcare ConferencePress releasePR Newswire+0.00%+0.60%
Queer Eye's Tan France helps unthread obesity bias as part of Zepbound's (tirzepatide) 'Changing the Thread Collection'Press releasePR Newswire+1.04%+1.86%
Lilly and U.S. government agree to expand access to obesity medicines to millions of AmericansPress releasePR Newswire+0.36%+1.51%
Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growthPress releasePR Newswire-0.73%-0.73%
Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweightPress releasePR Newswire+0.40%+1.02%
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwidePress releasePR Newswire+1.70%+3.47%
Lilly plans to build a new €2.6 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwidePress releasePR Newswire+0.05%+1.43%
Form 10-Q ELI LILLY & Co For: Sep 30SEC filing · Form 10-QSEC EDGAR+0.45%+0.00%
Form 8-K ELI LILLY & Co For: Oct 30SEC filing · Form 8-KSEC EDGAR-1.72%+0.66%

Each headline opens its own page with the full realized reaction — the move the market actually made, measured from the news timestamp.

Stop guessing what the event means.

claude mcp add news-quantified
Get free API keyTry the playground